Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization

1. A pharmaceutical composition, wherein said pharmaceutical composition is an oil-in-water emulsion comprising:

an aqueous phase comprising as active agent, an antisense oligonucleotide having the sequence SEQ ID NO: 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO: 1, wherein said function-conservative sequence comprises SEQ ID NO: 20, and wherein said antisense oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml; and

an oily phase dispersed in the aqueous phase.

2. The pharmaceutical composition according to claim 1 , wherein the aqueous phase further comprises a viscosity modifying agent.

3. The pharmaceutical composition according to claim 1 , wherein the aqueous phase further comprises a viscosity modifying agent selected from the group consisting of a hydrogel of sodium hyaluronate, polymers of acrylic acid, hydroxyethyl cellulose, dextran, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol and collagen.

4. The pharmaceutical composition according to claim 1 , wherein the oily phase comprises oils selected from the group consisting of vegetable oil; triglycerides; monoglycerides; diglycerides; oily fatty acids; isopropyl myristate; oily fatty alcohols; esters of sorbitol and fatty acids; oily sucrose esters, mineral oils, and mixtures thereof.

5. The pharmaceutical composition according to claim 1 , wherein the oily phase comprises a surfactant.

6. The pharmaceutical composition according to claim 1 , wherein the oily phase comprises a surfactant selected from the group consisting of naturally-occurring gums; naturally-occurring phosphatides; esters or partial esters derived from fatty acids and hexitol anhydrides; condensation products of the said partial esters with ethylene oxide; sorbitan ester; bentonite; glycerin monostearate; glyceryl monooleate and propylene glycol monolaurate or mixtures thereof; glyceryl stearate; poloxamer 188; poloxamer 282; poloxamer 407; tyloxapol; vitamin E D-polyethylene glycol succinate; polyethylene glycol (PEG); cetostearyl alcohol; cholesterol; ethylene glycol palmitostearate; lauric acid; myristic acid; myristyl alcohol; linoleic acid; oleic acid; palmitic acid; polysorbate 20 (Tween 20); sorbitan trioleate (Span 85); phospholipids; and mixture thereof.

7. The pharmaceutical composition according to claim 1 , wherein the oily phase comprises a thickening agent.

8. The pharmaceutical composition according to claim 1 , wherein the oily phase comprises a thickening agent selected from the group consisting of beeswax, hard paraffin and cetylic alcohol.

9. The pharmaceutical composition according to claim 1 , further comprising an osmolality modifying agent.

10. The pharmaceutical composition according to claim 1 , further comprising an osmolality modifying agent selected from the group consisting of NaCl, KCl, CaCl2, glycerol, mannitol, alpha-trehalose and propylene-glycol.

11. The pharmaceutical composition according to claim 1 , further comprising urea.

12. A unit dose container comprising the pharmaceutical composition according to claim 1 .

13. A unit dose container according to claim 12 , capable of dispensing eye drops.

14. A method for preventing, stabilizing and/or inhibiting blood and/or lymph vascularization, comprising the topical administration to a subject in need thereof of a pharmaceutical composition, wherein said pharmaceutical composition is an oil-in-water emulsion comprising:

an aqueous phase comprising as active agent, an antisense oligonucleotide having the sequence SEQ ID NO: 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO: 1, wherein said function-conservative sequence comprises SEQ ID NO: 20, and wherein said antisense oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml; and

an oily phase dispersed in the aqueous phase.

15. A method for treating a disease of the posterior segment of the eye, comprising the topical administration to a subject in need thereof of a pharmaceutical composition, wherein said pharmaceutical composition is an oil-in-water emulsion comprising:

an aqueous phase comprising as active agent, an antisense oligonucleotide having the sequence SEQ ID NO: 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO: 1, wherein said function-conservative sequence comprises SEQ ID NO: 20, and wherein said antisense oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml; and

an oily phase dispersed in the aqueous phase.

16. The method according to claim 15 for treating retinopathy comprising the topical administration to a subject in need thereof of a pharmaceutical composition, wherein said pharmaceutical composition is an oil-in-water emulsion comprising:

an aqueous phase comprising as active agent, an antisense oligonucleotide having the sequence SEQ ID NO: 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO: 1, wherein said function-conservative sequence comprises SEQ ID NO: 20, and wherein said antisense oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml; and

an oily phase dispersed in the aqueous phase.

17. The method according to claim 15 for treating age related macular degeneration, comprising the topical administration to a subject in need thereof of a pharmaceutical composition, wherein said pharmaceutical composition is an oil-in-water emulsion comprising:

an aqueous phase comprising as active agent, an antisense oligonucleotide having the sequence SEQ ID NO: 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO: 1, wherein said function-conservative sequence comprises SEQ ID NO: 20, and wherein said antisense oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml; and

an oily phase dispersed in the aqueous phase.

18. The method according to claim 15 for treating choroidal neovascularization by reducing the number of grade III or grade IV lesions, comprising the topical administration to a subject in need thereof of a pharmaceutical composition, wherein said pharmaceutical composition is an oil-in-water emulsion comprising:

an aqueous phase comprising as active agent, an antisense oligonucleotide having the sequence SEQ ID NO: 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO: 1, wherein said function-conservative sequence comprises SEQ ID NO: 20, and wherein said antisense oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml; and

an oily phase dispersed in the aqueous phase.

19. A pharmaceutical composition, wherein said pharmaceutical composition is an oil-in-water emulsion comprising:

from about 70 to 99% in weight to the total weight of the emulsion being an aqueous phase comprising as active agent, an antisense oligonucleotide having the sequence SEQ ID NO: 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO: 1, wherein said function-conservative sequence comprises SEQ ID NO: 20, and wherein said antisense oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml;

from about 1 to about 30% in weight to the total weight of the emulsion being an oily phase dispersed in the aqueous phase;

wherein the aqueous phase comprises:

said antisense oligonucleotide in an amount ranging from about 0.01 to about 0.3% in weight to the total weight of the emulsion;

polymers of acrylic acid in an amount ranging from about 0.01 to about 0.1% in weight to the total weight of the emulsion;

NaOH in an amount ranging from about 0.1 to about 0.5% in weight to the total weight of the emulsion; and

optionally urea, in an amount ranging from about 0.5 to about 20% in weight to the total weight of the emulsion; and

wherein the oily phase comprises:

Medium Chain Triglycerides (MCT), in an amount ranging from about 1 to about 20% in weight to the total weight of the emulsion;

a mixture of glyceryl stearate and of PEG-75 in an amount ranging from about 1 to about 10% in weight to the total weight of the emulsion;

cetylic alcohol in an amount ranging from about 0.1 to about 10% in weight to the total weight of the emulsion; and

optionally glycerol in an amount ranging from about 0.5 to about 25% in weight to the total weight of the emulsion.